Akers Biosciences (NASDAQ:AKER) Trading 8.6% Higher


Share on StockTwits

Akers Biosciences, Inc. (NASDAQ:AKER) traded up 8.6% on Wednesday . The stock traded as high as $2.65 and last traded at $2.65. 653,075 shares were traded during trading, an increase of 21% from the average session volume of 538,159 shares. The stock had previously closed at $2.44.

The company has a 50-day moving average of $2.06 and a two-hundred day moving average of $2.94.

Akers Biosciences (NASDAQ:AKER) last released its earnings results on Monday, November 16th. The medical instruments supplier reported ($0.38) earnings per share for the quarter.

Several hedge funds have recently bought and sold shares of the company. First Allied Advisory Services Inc. acquired a new stake in Akers Biosciences during the 3rd quarter valued at approximately $26,000. Private Advisor Group LLC acquired a new stake in Akers Biosciences during the 3rd quarter valued at approximately $28,000. Wedbush Securities Inc. acquired a new stake in Akers Biosciences during the 3rd quarter valued at approximately $29,000. Finally, We Are One Seven LLC acquired a new stake in Akers Biosciences during the 3rd quarter valued at approximately $55,000. Institutional investors and hedge funds own 5.52% of the company’s stock.

Akers Biosciences Company Profile (NASDAQ:AKER)

Akers Biosciences, Inc focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.

Recommended Story: What are no-load funds?

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.